290 related articles for article (PubMed ID: 32004567)
1. Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study.
Khemis A; Fontas E; Moulin S; Montaudié H; Lacour JP; Passeron T
J Invest Dermatol; 2020 Aug; 140(8):1533-1537.e2. PubMed ID: 32004567
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo.
Bakis-Petsoglou S; Le Guay JL; Wittal R
Br J Dermatol; 2009 Oct; 161(4):910-7. PubMed ID: 19523170
[TBL] [Abstract][Full Text] [Related]
3. Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis.
Bagel J; Nelson E; Keegan BR
J Drugs Dermatol; 2017 Oct; 16(10):957-962. PubMed ID: 29036248
[TBL] [Abstract][Full Text] [Related]
4. Tetrahydrocurcuminoid cream plus targeted narrowband UVB phototherapy for vitiligo: a preliminary randomized controlled study.
Asawanonda P; Klahan SO
Photomed Laser Surg; 2010 Oct; 28(5):679-84. PubMed ID: 20961233
[TBL] [Abstract][Full Text] [Related]
5. The effect of NB-UVB on noncultured melanocyte and keratinocyte transplantation in treatment of generalized vitiligo using two different donor-to-recipient ratios.
Tawfik YM; Abd Elazim NE; Abdel-Motaleb AA; Mohammed RAA; Tohamy AMA
J Cosmet Dermatol; 2019 Apr; 18(2):638-646. PubMed ID: 30280485
[TBL] [Abstract][Full Text] [Related]
6. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study.
Middelkamp-Hup MA; Bos JD; Rius-Diaz F; Gonzalez S; Westerhof W
J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):942-50. PubMed ID: 17659004
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial.
Esfandiarpour I; Ekhlasi A; Farajzadeh S; Shamsadini S
J Dermatolog Treat; 2009; 20(1):14-8. PubMed ID: 18608735
[TBL] [Abstract][Full Text] [Related]
8. Narrowband ultraviolet B phototherapy combined with intralesional injection of either latanoprost or platelet-rich plasma for stable nonsegmental vitiligo.
Fawzy M; Al-Mokadem S; Alshereef M; Elkholy B
Photodermatol Photoimmunol Photomed; 2024 Jan; 40(1):e12929. PubMed ID: 37984828
[TBL] [Abstract][Full Text] [Related]
9. Effects of a preceding fractional carbon dioxide laser on the outcome of combined local narrowband ultraviolet B and topical steroids in patients with vitiligo in difficult-to-treat areas.
Vachiramon V; Chaiyabutr C; Rattanaumpawan P; Kanokrungsee S
Lasers Surg Med; 2016 Feb; 48(2):197-202. PubMed ID: 26175036
[TBL] [Abstract][Full Text] [Related]
10. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy.
Yones SS; Palmer RA; Garibaldinos TM; Hawk JL
Arch Dermatol; 2007 May; 143(5):578-84. PubMed ID: 17519217
[TBL] [Abstract][Full Text] [Related]
11. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
[TBL] [Abstract][Full Text] [Related]
12. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.
Lim HW; Grimes PE; Agbai O; Hamzavi I; Henderson M; Haddican M; Linkner RV; Lebwohl M
JAMA Dermatol; 2015 Jan; 151(1):42-50. PubMed ID: 25230094
[TBL] [Abstract][Full Text] [Related]
13. Whole-body and targeted narrowband ultraviolet B phototherapy effectively stabilize acral vitiligo with negligible repigmentation beyond wrists and ankles: Results from a split-body randomized controlled trial.
Thind A; Vinay K; Mehta H; Bishnoi A; Kumaran MS; Parsad D
Photodermatol Photoimmunol Photomed; 2024 Mar; 40(2):e12960. PubMed ID: 38480997
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of interrupted versus continuous narrowband ultraviolet B phototherapy in nonsegmental vitiligo treatment: A prospective randomized comparative study.
Anbar TS; Mohammed SS; Mohamed DM; Abdel-Rahman AT
Dermatol Ther; 2019 Nov; 32(6):e13117. PubMed ID: 31606939
[TBL] [Abstract][Full Text] [Related]
15. Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial.
Dell'Anna ML; Mastrofrancesco A; Sala R; Venturini M; Ottaviani M; Vidolin AP; Leone G; Calzavara PG; Westerhof W; Picardo M
Clin Exp Dermatol; 2007 Nov; 32(6):631-6. PubMed ID: 17953631
[TBL] [Abstract][Full Text] [Related]
16. Targeted broadband ultraviolet b phototherapy produces similar responses to targeted narrowband ultraviolet B phototherapy for vitiligo: a randomized, double-blind study.
Asawanonda P; Kijluakiat J; Korkij W; Sindhupak W
Acta Derm Venereol; 2008; 88(4):376-81. PubMed ID: 18709309
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcome and persistence of repigmentation from narrow-band ultraviolet B phototherapy in vitiligo.
Silpa-Archa N; Weerasubpong P; Junsuwan N; Yothachai P; Supapueng O; Wongpraparut C
J Dermatolog Treat; 2019 Nov; 30(7):691-696. PubMed ID: 30474443
[No Abstract] [Full Text] [Related]
18. NB-UVB plus oral Polypodium leucotomos extract display higher efficacy than NB-UVB alone in patients with vitiligo.
Pacifico A; Damiani G; Iacovelli P; Conic RRZ; ; Gonzalez S; Morrone A
Dermatol Ther; 2021 Mar; 34(2):e14776. PubMed ID: 33433041
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of using fractional CO
Ghasemloo S; Gauthier Y; Ghalamkarpour F
J Dermatolog Treat; 2019 Nov; 30(7):697-700. PubMed ID: 30592235
[No Abstract] [Full Text] [Related]
20. Combination treatment by 10 600 nm ablative fractional carbon dioxide laser and narrowband ultraviolet B in refractory nonsegmental vitiligo: a prospective, randomized half-body comparative study.
Shin J; Lee JS; Hann SK; Oh SH
Br J Dermatol; 2012 Mar; 166(3):658-61. PubMed ID: 22050270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
